![AstraZeneca](https://www.adcreviews.com/wp-content/uploads/2022/10/AstraZeneca-240x140.jpg)
AstraZeneca’s Akt inhibitor successful in phase III study in breast cancer
On October 26, AstraZeneca announced that the Phase III CAPItello-291 study of its Akt1/2/3 inhibitor capivasertib in combination with fulvestrant in breast cancer patients met